Why Idera Pharmaceuticals Stock Is Crashing Today | The Motley Fool

Accessibility MenuSearch for a company ▲ S&P 500 +196% | ▲ Stock Advisor +950% Join The Motley Fool Accessibility...HelpArrow-Thin-DownS&P 5006,915.61+0.0%+2.26Arrow-Thin-DownDJI49,098.71-0.6%-285.30Arrow-Thin-DownNASDAQ23,501.24+0.3%+65.22Arrow-Thin-DownBitcoin$89,208.00+0.0%+$11.84Arrow-Thin-DownHYMC$50.65+8.5%+$3.96Arrow-Thin-DownCRML$20.62+11.7%+$2.16Arrow-Thin-DownBABA$173.38-2.1%-$3.80Arrow-Thin-DownRGC$31.41+2.1%+$0.64Arrow-Thin-DownABT$107.42-1.1%-$1.19Arrow-Thin-DownLMND$93.10-3.6%-$3.47Arrow-Thin-DownAMZN$239.30+2.1%+$4.96Arrow-Thin-DownGOOG$328.43-0.7%-$2.41Arrow-Thin-DownMETA$658.76+1.7%+$11.13Arrow-Thin-DownMSFT$466.69+3.4%+$15.55Arrow-Thin-DownNVDA$187.79+1.6%+$2.95Arrow-Thin-DownTSLA$449.06-0.1%-$0.30Daily Stock GainersDaily Stock LosersMost Active Stocksarrow-leftarrow-rightDaily Stock GainersDaily Stock LosersMost Active StocksBy Keith Speights – Updated Mar 19, 2021 at 11:12AM EST

NASDAQ: IDRA

Idera Pharmaceuticals

The company's experimental cancer drug flopped in a late-stage study.

What happened

Shares of Idera Pharmaceuticals (IDRA +0.00%) were crashing 63.5% at 10:49 a.m. EDT on Friday. The plunge came after the company announced disappointing results Thursday from a late-stage study of tilsotolimod in combination with Bristol Myers Squibb's Yervoy in treating advanced melanoma. 

So what

Idera had hoped that the tilsotolimod-Yervoy combo would sail through its pivotal study. That didn't happen.

The company reported an objective response rate (the percentage of patients with tumor-size reduction of a predefined amount) for patients taking the combo of only 8.8%. Patients receiving Yervoy by itself had an objective response rate of 8.6%.

Image source: Getty Images.

Vincent Milano, Idera Pharmaceuticals CEO, said that he and his team "are surprised and disappointed" by the results from the late-stage study. What wasn't a surprise was the reaction from Wall Street. Multiple analysts quickly downgraded the biotech stock.

Now what

What's next for Idera? The company stated that it's evaluating whether or not to keep the late-stage study going to see if the tilsotolimod-Yervoy combo can meet its overall survival endpoint. There's still at least a sliver of hope that this could happen and set the stage for a path to regulatory approval. Idera will also move forward with its phase 2 study of tilsotolimod and Yervoy in treating microsatellite stable colorectal cancer.

Read Next

Aug 12, 2018 •By Cory Renauer3 Beaten-Down Biotech Stocks: Can They Recover?Aug 2, 2018 •By George Budwell, PhDWhy BioCryst Pharmaceuticals Stock Is Bolting Higher TodayJul 11, 2018 •By Brian FeroldiWhy Idera Pharmaceuticals Is Sinking TodayJun 4, 2018 •By Maxx ChatskoHere's Why Idera Pharmaceuticals Fell as Much as 15.4% TodayJan 22, 2018 •By Sean WilliamsBioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No LoveNov 9, 2017 •By Brian Orelli, PhDWhy Idera Pharmaceuticals Inc. Jumped Higher Today

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.TMFFishBiz

Stocks Mentioned

Bristol Myers Squibb

NYSE: BMY$54.65 (0.01%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services